HMG-CoA reductase inhibitors and coenzyme Q10.

@article{Nawarskas2005HMGCoARI,
  title={HMG-CoA reductase inhibitors and coenzyme Q10.},
  author={James J. Nawarskas},
  journal={Cardiology in review},
  year={2005},
  volume={13 2},
  pages={76-9}
}
The most concerning adverse reaction with HMG-CoA reductase inhibitors (statins) is myotoxicity. Statins inhibit the production of mevalonate, a precursor of both cholesterol and coenzyme Q10, a compound believed to be crucial for mitochondrial function and the provision of energy for cellular processes. There is speculation that a reduction in coenzyme Q10 concentrations may promote the myopathies that have been associated with statin treatment as a result of mitochondrial damage. Although… CONTINUE READING